Allergic contact dermatitis from aluminium in deodorants.

Department of Dermatology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
Contact Dermatitis (Impact Factor: 3.62). 01/2010; 62(1):57-8. DOI: 10.1111/j.1600-0536.2009.01663.x
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ARTICLE INFO ABSTRACT It was found that the world wide annual expenditures for cosmetics is estimated at U.S.$18 billion, and many players in the field are competing aggressively to capture companies are interested to know about consumer's preferences strategies to win over competition. The main purpose of this research paper is to investigate the influence of preferences on cosmetics buying behavior especially men's deodorants like the factors those influence the cons examine the level of awareness of brands available. We have conducted research to know the factors for retailers preferences also. Originality/value deodorants in the Saudi Market, particularly in the Al Baha region. This research paper has reviewed suitable literature within a customized research to garner the preferences of both the consumers as well as the retailers. We have used two different questionnaires used in this market. Copyright © 2014 Prof. Kameswara Rao Poranki and Dr. Abdulbaset Hasouneh. Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    International Journal of Current Research 04/2014; Vol.6(Issue, 04):pp.6420-6427.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Childhood vaccines are a routine part of pediatric care in the United States; clinicians must be able to recognize and interpret associated localized adverse reactions. Redness and induration at the site of injection are commonly reported and are considered to be the result of local inflammation or hematoma formation, although other atypical reactions can occur. We report the case of a 6-month-old infant who developed subcutaneous nodules at the sites of his 4- and 6-month Pentacel (DTaP/Hib/IPV, diphtheria, tetanus, acellular pertussis, Haemophilus b conjugate, and inactivated poliovirus vaccine) and 6-month Prevnar (heptavalent pneumococcal vaccine) injections. Infectious disease and immunodeficiency examinations were unremarkable. Aluminum contact allergy was considered, and contact allergy testing confirmed sensitivity to aluminum. Although rare, aluminum contact allergy after routine immunization can occur and should be considered in the differential diagnosis of persistent subcutaneous nodules after vaccination.
    Pediatric Dermatology 08/2011; 29(1):68-72. DOI:10.1111/j.1525-1470.2011.01541.x · 1.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aluminum-containing adjuvants are widely used in preventive vaccines against infectious diseases and in preparations for allergy immunotherapy. The mechanism by which they enhance the immune response remains poorly understood. Aluminum adjuvants selectively stimulate a Th2 immune response upon injection of mice and a mixed response in human beings. They support activation of CD8 T cells, but these cells do not undergo terminal differentiation to cytotoxic T cells. Adsorption of antigens to aluminum adjuvants enhances the immune response by facilitating phagocytosis and slowing the diffusion of antigens from the injection site which allows time for inflammatory cells to accumulate. The adsorptive strength is important as high affinity interactions interfere with the immune response. Adsorption can also affect the physical and chemical stability of antigens. Aluminum adjuvants activate dendritic cells via direct and indirect mechanisms. Phagocytosis of aluminum adjuvants followed by disruption of the phagolysosome activates NLRP3-inflammasomes resulting in the release of active IL-1β and IL-18. Aluminum adjuvants also activate dendritic cells by binding to membrane lipid rafts. Injection of aluminum-adjuvanted vaccines causes the release of uric acid, DNA, and ATP from damaged cells which in turn activate dendritic cells. The use of aluminum adjuvant is limited by weak stimulation of cell-mediated immunity. This can be enhanced by addition of other immunomodulatory molecules. Adsorption of these molecules is determined by the same mechanisms that control adsorption of antigens and can affect the efficacy of such combination adjuvants. The widespread use of aluminum adjuvants can be attributed in part to the excellent safety record based on a 70-year history of use. They cause local inflammation at the injection site, but also reduce the severity of systemic and local reactions by binding biologically active molecules in vaccines.
    Frontiers in Immunology 01/2012; 3:406. DOI:10.3389/fimmu.2012.00406